Conmed (CNMD) Q1 2026 Earnings Transcript

CONMED reported Q1 sales of $317 million, down 1.3% year over year, but organic sales grew 2.1% and management raised full-year organic growth guidance to 5.0%-6.5%. Gross margin improved 100 bps to 57.4%, and the company maintained full-year adjusted EPS guidance of $4.30-$4.45 despite expecting at least $0.10 of EPS pressure from debt refinancing. The GI portfolio exit lowers 2026 GI revenue by about $7 million at the midpoint, while buybacks totaled $37.4 million in the quarter.

Analysis

The market is likely to underappreciate how cleanly this quarter de-risks the post-GI story: the company is effectively trading a low-quality, lower-growth revenue stream for a tighter operating model with better mix and more durable pricing power. The key second-order effect is that the portfolio simplification should improve management bandwidth and channel focus just as AirSeal, smoke evacuation, and BioBrace are hitting inflection points; that matters more than the modest top-line haircut. The raised organic guide signals that the core business is already offsetting divestiture drag, which usually matters more for multiple support than the headline reported revenue number.

The real tension is leverage. Management is choosing cheaper-bank-debt optics over convertible dilution, but the near-term EPS neutrality is fragile because the added interest burden is being absorbed by margin expansion and share repurchases simultaneously. If working capital stays elevated and cash conversion remains soft, the equity can re-rate down quickly because the stock is now effectively a self-funded growth-and-buyback story with less room for execution slippage. Inventory build also suggests the company is prioritizing service levels ahead of demand certainty, which is constructive operationally but can mask latent channel demand risk for another quarter or two.

The most interesting underappreciated catalyst is regulatory optionality in smoke evacuation. With pending state legislation and hospital standardization trends, Buffalo Filter has a long-duration adoption curve that could drive a multi-year mix shift away from OEM exposure, which should improve gross margin durability and reduce quarter-to-quarter lumpiness. Meanwhile, AirSeal’s low U.S. laparoscopic penetration means modest share gains can sustain high-single-digit growth for years; the setup is more about installed base monetization than one-time product launches. The contrarian view is that consensus may be too focused on the GI exit headline and not enough on the compounding effect of better mix, but the stock likely needs a cleaner cash-flow inflection before a sustained rerating.

Key Decisions for Investors

• Long CNMD on a 3-6 month horizon into the Q2/Q3 execution window; thesis is multiple expansion from portfolio simplification and guide raises, with downside if cash conversion and inventory do not normalize.
• Pair trade: long CNMD / short a lower-quality medtech name with weaker organic growth and higher balance-sheet risk; use this as a relative-value expression on execution quality and mix improvement rather than absolute beta.
• Buy CNMD out-of-the-money call spreads for the next 2 earnings cycles; risk/reward favors upside if AirSeal and Buffalo Filter continue to accelerate, while limiting premium outlay given refinancing overhang.
• If CNMD rallies sharply on the refinancing headline, fade strength tactically unless operating cash flow improves next quarter; the equity remains vulnerable to a 1-2 quarter working-capital hangover.
• Monitor for a cleaner long entry only after inventory days and receivables stabilize; that would confirm the growth is converting into cash rather than just revenue.